Cytosorbents Corporation Common Stock (CTSO)
Stock · NASDAQ · Health Care
$4.05as of 10/16/2026
Price chart
Active signals
CTSO Signal Track Record
How signals performed across all stocks →What CTSO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 53 | -5.5% | 38% | August 28, 2026 |
| Bollinger Band Breakdown | 21 | +2.8% | 52% | August 20, 2026 |
| Bollinger Band Breakout | 18 | -12.7% | 22% | September 8, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -3.8% | 31% | September 9, 2025 |
| Any 20-session window (baseline) | -4.0% | 39% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CTSO
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and in…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 129
- Website
- cytosorbents.com/
Fundamentals
- 1-day range
- $3.01$4.6
- Market cap
- $25.05M
- P/E (trailing)
- —
- P/E (forward)
- Infinity
- EPS (trailing)
- $-0.29
- Dividend yield
- —
- Beta
- 1.51
- Avg. volume
- 23.6K
How Cytosorbents Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 30, 2026 · via SEC EDGAR / Finnhub
Forecasts
2 analyst ratings
Cytosorbents Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- CTSOCytosorbents Corporation Common Stock$4.11▲ 34.31%Market cap $25.05MP/E —$2.96$18.8
- CNSYCerenome Inc. Common Stock$1.7▼ 9.57%Market cap $26.57MP/E —$1.49$4.16
- BEATHeartbeam Inc. Common Stock$0.436▲ 0.93%Market cap $28.33MP/E —$0.355$4
- PLRZPolyrizon Ltd. Ordinary Shares$10▼ 0.10%Market cap $21.51MP/E —$2.88$18.2
- RVPRetractable Technologies Inc. Common Stock$0.58▼ 1.69%Market cap $20.27MP/E —$0.5844$1.14
- ARAYAccuray Incorporated Common Stock$0.16▼ 5.88%Market cap $33.63MP/E —$0.1615$1.86
- ADGMAdagio Medical Holdings Inc Common Stock$0.099▼ 3.88%Market cap $16.26MP/E —$0.083$2.02
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CTSO Cytosorbents Corporation Common Stock | $25.05M | — | $4.11 | ▲ 34.31% | $2.96$18.8 |
| CNSY Cerenome Inc. Common Stock | $26.57M | — | $1.7 | ▼ 9.57% | $1.49$4.16 |
| BEAT Heartbeam Inc. Common Stock | $28.33M | — | $0.436 | ▲ 0.93% | $0.355$4 |
| PLRZ Polyrizon Ltd. Ordinary Shares | $21.51M | — | $10 | ▼ 0.10% | $2.88$18.2 |
| RVP Retractable Technologies Inc. Common Stock | $20.27M | — | $0.58 | ▼ 1.69% | $0.5844$1.14 |
| ARAY Accuray Incorporated Common Stock | $33.63M | — | $0.16 | ▼ 5.88% | $0.1615$1.86 |
| ADGM Adagio Medical Holdings Inc Common Stock | $16.26M | — | $0.099 | ▼ 3.88% | $0.083$2.02 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical CareYahoo · 9/30/2026
- CytoSorbents Regains Nasdaq Compliancebenzinga · 9/23/2026
- CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price RequirementYahoo · 9/23/2026
- CytoSorbents Regains Nasdaq ComplianceBenzinga · 9/23/2026
Insider Activity
Insider Actions →- Phillip P. Chan · September 15, 2026 · Buy3.8K @ $6
- Alan D. Sobel · September 15, 2026 · Buy100 @ $6.01
- Alan D. Sobel · September 15, 2026 · Buy500 @ $6.05
- Alan D. Sobel · September 15, 2026 · Buy1.9K @ $6.12
- Vincent Capponi · September 14, 2026 · Buy273 @ $5.9
- Vincent Capponi · September 14, 2026 · Buy1.8K @ $6.07
- Phillip P. Chan · September 4, 2026 · Buy200.0K @ $0.35
- Peter J. Mariani · June 15, 2026 · Buy100.0K @ $0.44
- Phillip P. Chan · June 15, 2026 · Buy10.3K @ $0.43
- Phillip P. Chan · June 12, 2026 · Buy251.1K @ $0.4
Institutional Ownership
March 31, 2026
- Total shares held
- 16.14M
- Total value held
- $9.13M
- Institutional holders
- 47
- Unknown5.22M
- Unknown1.88M
- Unknown1.71M
- Unknown1.68M
- Unknown1.48M
- Unknown783.0K
- Unknown707.3K
- Unknown549.9K
- Unknown500.0K
- Unknown172.6K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Cytosorbents to Present New Data at Cardiac Surgery Conferences
Cytosorbents announced that it will present new data at upcoming international conferences focused on cardiac surgery and critical care. These presentations offer a platform to share recent findings with the medical community. For a company in the medical device sector, such events are key moments for communicating progress and engaging with specialists in the field.
Cytosorbents to Present New Data at Cardiac Surgery Conferences. Cytosorbents announced that it will present new data at upcoming international conferences focused on cardiac surgery and critical care. These presentations offer a platform to share recent findings with the medical community. For a company in the medical device sector, such events are key moments for communicating progress and engaging with specialists in the field.